Navigation Links
iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
Date:4/29/2010

SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire/ -- iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine (CIRM). The grant will be used to fund the study of mechanisms of cellular reprogramming with the specific aim of enhancing the efficiency of reprogramming techniques.

"Patient-derived induced pluripotent stem cells (iPS cells) offer immediate utility for discovering new therapeutics to treat serious diseases, as well as future potential for cellular therapy. This research program is designed to provide valuable insights into the biological pathways and molecular targets involved in inducing pluripotent stem cells," said John P. Walker, chief executive officer of iPierian.

Through the grant, entitled "Cellular Reprogramming: Dissecting the Molecular Mechanism and Enhancing Efficiency," iPierian will identify and study small molecules that promote the reprogramming of human somatic cells to pluripotent cells. First, a large number of compounds will be screened using an established assay to detect early markers for the induction of pluripotency. Next, the mechanisms of action of confirmed lead compounds will be studied using a variety of genomic profiling, bioinformatics and RNAi based approaches. Candidate small molecules will then be used to generate iPS cell lines. A more detailed summary of the grant application can be found on the CIRM website at http://www.cirm.ca.gov/ReviewReports_RB2-01628.

Mr. Walker continued, "iPierian greatly appreciates and recognizes the significance of the support of stem cell research by the voters of the State of California. CIRM funding of this program will enable us to advance the science and our understanding of cellular reprogramming.  CIRM's overall research funding enhances California's leadership in applying stem cell research to the discovery of new therapeutics and the potential of finding new treatment regimens for many diseases for which no effective treatments yet exist."

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to metabolic disease.  Our internationally-renowned scientific founders include leaders of the Harvard Stem Cell Institute and the Gladstone Institute, whose diverse professional expertise support and inform the company's scientific direction, Drs. George Daley, Douglas Melton and Lee Rubin, who are also faculty members at Harvard University, and Dr. Deepak Srivastava, a faculty member at University of California, San Francisco.

Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary small molecule or biologic therapeutics.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
2. iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
3. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
4. Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher
5. 5th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Peter K. Vogt, Ph.D., The Scripps Research Institute
6. Shanghai ChemPartners Animal Facility Awarded AAALAC Accreditation
7. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
8. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
9. Intralink-Spine Inc. Awarded $750,000 Small Business Innovation Research Phase II Grant
10. Palmer Labs Awarded U.S. Department of Energy Funding for Algae Biofuel Research
11. Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... a collaboration with Koch Agronomic Services (Koch) to feature new innovations aimed at ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. ... , a provider of whole slide imaging solutions, are hosting a pre-conference workshop ... entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, ...
(Date:9/20/2017)... ... 20, 2017 , ... RoviSys, a leading independent provider of ... of an office in Taipei, Taiwan. This new location allows RoviSys to better ... relationships in the region. Located in the Neihu area of Taipei, the office ...
(Date:9/19/2017)... ... ... Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview ... Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and have remained in ... of stem cell therapy and a fast friendship was formed. , Dr. Harman has been ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):